Cargando…

Pharmacogenetic Dose Modeling Based on CYP2C19 Allelic Phenotypes

Pharmacogenetic variability in drug metabolism leads to patient vulnerability to side effects and to therapeutic failure. Our purpose was to introduce a systematic statistical methodology to estimate quantitative dose adjustments based on pharmacokinetic differences in pharmacogenetic subgroups, add...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stingl, Julia Carolin, Radermacher, Jason, Wozniak, Justyna, Viviani, Roberto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9781550/ https://www.ncbi.nlm.nih.gov/pubmed/36559326 http://dx.doi.org/10.3390/pharmaceutics14122833

Ejemplares similares

Genetic polymorphism of CYP2C19 and subcortical variability in the human adult brain
por: Stingl, Julia C., et al.
Publicado: (2021)

6. Dose Adjustments Based on Pharmacogenetics of CYP450 Enzymes
por: van Schaik, Ron H.N.
Publicado: (2008)

Pharmacogenetic Expression of CYP2C19 in a Pediatric Population
por: Pierre-François, Marie Josette Déborah, et al.
Publicado: (2022)

Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19
por: Swen, J. J., et al.
Publicado: (2011)

From gene to dose: Long-read sequencing and *-allele tools to refine phenotype predictions of CYP2C19
por: Graansma, Lonneke J., et al.
Publicado: (2023)

The pharmacogenetics of CYP2D6 and CYP2C19 in a case series of antidepressant responses
por: Kee, Ping Siu, et al.
Publicado: (2023)

CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype
por: Helsby, N A, et al.
Publicado: (2008)

Clinical Application of CYP2C19 Pharmacogenetics Toward More Personalized Medicine
por: Lee, Su-Jun
Publicado: (2013)

Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine
por: El Rouby, Nihal, et al.
Publicado: (2018)

Optimizing clopidogrel dose response: a new clinical algorithm comprising CYP2C19 pharmacogenetics and drug interactions
por: Saab, Yolande B, et al.
Publicado: (2015)

Associations of CYP2C9 and CYP2C19 Pharmacogenetic Variation with Phenytoin‐Induced Cutaneous Adverse Drug Reactions
por: Fohner, Alison E., et al.
Publicado: (2020)

Evaluation of CYP2C9- and VKORC1-based pharmacogenetic algorithm for warfarin dose in Gaza-Palestine
por: Ayesh, Basim Mohammad, et al.
Publicado: (2018)

Phenprocoumon Dose Requirements, Dose Stability and Time in Therapeutic Range in Elderly Patients With CYP2C9 and VKORC1 Polymorphisms
por: Schneider, Katharina Luise, et al.
Publicado: (2020)

Acute pharmacogenetic dystonic reactions in a family with the CYP2D6 *41 allele: a case report
por: Wong, Darice Y., et al.
Publicado: (2021)

Characterization of CYP3A pharmacogenetic variation in American Indian and Alaska Native communities, targeting CYP3A4*1G allele function
por: Fohner, Alison E., et al.
Publicado: (2021)

Pharmacogenetics of Long-Term Outcomes of Schizophrenia Spectrum Disorders: The Functional Role of CYP2D6 and CYP2C19
por: Sandhu, Amrit K., et al.
Publicado: (2023)

Distribution of CYP2D6 Alleles and Phenotypes in the Brazilian Population
por: Friedrich, Deise C., et al.
Publicado: (2014)

Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group
por: Caudle, Kelly E., et al.
Publicado: (2019)

Implementation and management outcomes of pharmacogenetic CYP2C19 testing for clopidogrel therapy in clinical practice
por: Russmann, Stefan, et al.
Publicado: (2020)

Effects of genetic variability of CYP2D6 on neural substrates of sustained attention during on-task activity
por: Viviani, Roberto, et al.
Publicado: (2020)

A129 CYP2C19 PHARMACOGENETIC TESTING IN PAEDIATRIC PATIENTS WITH EOSINOPHILIC ESOPHAGITIS INFLUENCES DOSING OF PROTON-PUMP-INHIBITORS AND RESPONSE TO THERAPY
por: Bortolin, K A, et al.
Publicado: (2022)

Association of CYP2C9*2 Allele with Sulphonylurea-Induced Hypoglycaemia in Type 2 Diabetes Mellitus Patients: A Pharmacogenetic Study in Pakistani Pashtun Population
por: Jan, Asif, et al.
Publicado: (2023)

Distribution of alleles, genotypes and haplotypes of the CYP2B6 (rs3745274; rs2279343) and CYP3A4 (rs2740574) genes in the Malian population: Implication for pharmacogenetics
por: Kassogue, Yaya, et al.
Publicado: (2021)

CYP2C9 Variations and Their Pharmacogenetic Implications Among Diverse South Asian Populations
por: Nizamuddin, Sheikh, et al.
Publicado: (2021)

Pharmacogenetic-Based Efavirenz Dose Modification: Suggestions for an African Population and the Different CYP2B6 Genotypes
por: Mukonzo, Jackson K., et al.
Publicado: (2014)

Pharmacogenetic evaluation of ABCB1, Cyp2C9, Cyp2C19 and methylene tetrahydrofolate reductase polymorphisms in teratogenicity of anti-epileptic drugs in women with epilepsy
por: Jose, Manna, et al.
Publicado: (2014)

Pharmacogenetics of CYP2C19 genetic polymorphism on clopidogrel response in patients with ischemic stroke from Saudi Arabia
por: Alhazzani, Adel A., et al.
Publicado: (2017)

Genomics of Dementia: APOE- and CYP2D6-Related Pharmacogenetics
por: Cacabelos, Ramón, et al.
Publicado: (2012)

Frequencies of clinically important CYP2C19 and CYP2D6 alleles are graded across Europe
por: Petrović, Jelena, et al.
Publicado: (2019)

Pharmacogenetic testing revisited: 5′ nuclease real-time polymerase chain reaction test panels for genotyping CYP2D6 and CYP2C19
por: Larsen, Jens Borggaard, et al.
Publicado: (2017)

Distribution of CYP2B6 516G/T pharmacogenetically important polymorphism in the Ukrainian population
por: Filiptsova, Olga, et al.
Publicado: (2018)

Development and validation of T‐ARMS‐PCR to detect CYP2C19*17 allele
por: Jin, Chenxi, et al.
Publicado: (2019)

ABCB1 C3435T and CYP2C19*2 polymorphisms in a Palestinian and Turkish population: A pharmacogenetic perspective to clopidogrel
por: Nassar, Suheir, et al.
Publicado: (2014)

Effect of CYP2D6 pharmacogenetic phenotype and phenoconversion on serum concentrations of antidepressants and antipsychotics: a retrospective cohort study
por: Scherf-Clavel, Maike, et al.
Publicado: (2023)

MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant?
por: de la Torre, Rafael, et al.
Publicado: (2012)

Evaluating the frequency and the impact of pharmacogenetic alleles in an ancestrally diverse Biobank population
por: Verma, Shefali S., et al.
Publicado: (2022)

Systematic Review of Pharmacogenetic Warfarin Dosing
por: van Schie, Rianne M. F., et al.
Publicado: (2009)

Testing of VKORC1 and CYP2C9 alleles to guide warfarin dosing: Test Category: Pharmacogenomic (Treatment)
por: Grossniklaus, Daurice
Publicado: (2010)

A Novel Allele-Specific PCR Protocol for the Detection of the HLA-C*03:02 Allele, a Pharmacogenetic Marker, in Vietnamese Kinh People
por: Pham, Tran Thu Ha, et al.
Publicado: (2021)

Recurrent CYP2C19 deletion allele is associated with triple-negative breast cancer
por: Tervasmäki, Anna, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_fq8qs1u8a4pkfmk0lfv3mv7d7n